Tagged with BMS

China Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in November 2018 in a bid to curb unsustainable healthcare expenditures, domestic and foreign drug manufacturers have been forced into an increasingly cutthroat race to the bottom, at least for the…

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…

Pharma Faces Veronique Walsh, general manager of Bristol Myers Squibb for Belgium, the Netherlands, and Luxembourg (Benelux), recently spoke to PharmaBoardroom about her diverse career path, transitioning from medical doctor to pharmaceutical executive, and leading a large affiliate through the COVID-19 crisis.   Looking back over her slightly unusual career trajectory, Walsh,…

Belgium Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the prospects for bringing innovation to Belgian patients and explains how BMS continues to deliver on its promise of transforming lives…

Romania With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the charge against cancer. The combined entity is expected to rise in the global biopharma rankings, complete with a fresh new…

Global The world’s bestselling treatments for 2019 by sales in USD billions. AbbVie’s Humira is out in front with USD 19.7 billion in sales, followed by Bristol Myers Squibb’s Eliquis, and Merck & Co. (MSD globally)’s Keytruda.   Made with Visme Infographic Maker

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Romania Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has become Romanian market leader in immuno-oncology by launching new indications and therapy lines for its products in the country. He…

Sweden Though far from the largest pharma market in Europe, Sweden nevertheless holds strategic importance for global pharma; from the country’s attitude to public health to its sophisticated digital framework, comprehensive patient registries and innovative spirit. Here, four pharma country managers hailing from outside Sweden’s borders give their first impressions of…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

Puerto Rico Leobardo Hidalgo, who lived in Puerto Rico as a child, recently came back to the island to head commercial operations at the local BMS affiliate, which has been performing remarkably well. He highlights a portfolio of transformational medicines matched with the local team’s patient-centric approach and knowledge of the ecosystem…

Sweden Iddo Leshem, general manager Nordics at Bristol-Myers Squibb (BMS), talks about the uniqueness of Sweden’s collaborative culture and shatters some of the entrenched stereotypes about the country. He then breaks down the drivers behind the outstanding performance of the affiliate and emphasizes the important role Sweden plays in the development…